Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Elixxer Ltd V.ELXR


Primary Symbol: V.ELXR.H Alternate Symbol(s):  ELIXF

Financial Services Asset Management
Elixxer Ltd. is a Canada-based investment company. The Company has investments and activities in the legal cannabis sector. The Company is focused on investing opportunities in various sectors, with a priority on growth companies that are past the start-up phase.


TSXV:ELXR.H - Post by User

Elixxer Ltd > LGF worth 15 million Why are we not skyrocketering?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(7)
•••
Comment by TommyV978on Jan 14, 2021 9:28am
152 Views
Post# 32292921

RE:RE:RE:RE:LGF worth 15 million Why are we not skyrocketering?

RE:RE:RE:RE:LGF worth 15 million Why are we not skyrocketering? took this off my RBC morning star info "

ELXR's debt to total capital ratio, at 44.09%, is in-line with the Major Drugs industry's norm despite its increase over the last year.
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities